SCHEMBL25525564

SCHEMBL25525564

N=C(NC(=O)c1ccc(=O)n(Cc2cccnc2)c1)c1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
NPC1 O15118 2/20 0.48
BRD4 O60885 2/20 0.48
BRD2 P25440 1/20 0.48
BRD3 Q15059 1/20 0.48
BRDT Q58F21 1/20 0.48
ADRA1D P25100 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CACNA1I Q9P0X4 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNA7 P36544 1/20 0.42
CHRNA4 P43681 1/20 0.42
KLKB1 P03952 1/20 0.42
MAPT P10636 1/20 0.42
MAPK8 P45983 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25525582 0.90 BRD4 (0.48) ALDH1A1NPC1BRD4BRD2BRD3
SCHEMBL25525580 0.89 TP53 (0.46) ALDH1A1BRD4BRD2BRD3BRDT
SCHEMBL25525568 0.89 LMNA (0.51) ALDH1A1BRD4BRD2BRD3BRDT
SCHEMBL25525591 0.88 BRD4 (0.57) ALDH1A1BRD4BRD2BRD3BRDT
SCHEMBL25525585 0.87 MAPT (0.49) ALDH1A1BRD4BRD2BRD3BRDT
SCHEMBL25525574 0.87 ALDH1A1 (0.49) ALDH1A1BRD4BRD2BRD3BRDT
SCHEMBL25525581 0.86 SMN1; SMN2 (0.47) ALDH1A1BRD4BRD2BRD3BRDT
SCHEMBL25525579 0.84 BRD4 (0.49) ALDH1A1BRD4BRD2BRD3BRDT
SCHEMBL25525592 0.83 BRD4 (0.52) ALDH1A1BRD4BRD2BRD3BRDT
SCHEMBL25525565 0.78 MAPT (0.49) ALDH1A1BRD4BRD2BRD3BRDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159513-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159513-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, IL1B, IL1RN ALDH1A1 370/4885NPC1 3706/4885BRD4 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.